Avenanthramides, polyphenols from oats, inhibit IL-1β-induced NF-κB activation in endothelial cells

Free Radical Biology and Medicine

Volumn 44, Issue 3, 2008, Pages 415-429

  Guo, Weimin ^a   Wise, Mitchell L ^b   Collins, F William ^c   Meydani, Mohsen ^a  

^a TUFTS UNIVERSITY   (United States)

^b AGRICULTURAL RESEARCH SERVICE   (United States)

^c OTTAWA RESEARCH AND DEVELOPMENT CENTRE   (Canada)

Author keywords

Atherosclerosis; Avenanthramide c methyl ester; Cytokines; Endothelial cell; NF B

Indexed keywords

AVENANTHRAMIDE; CYTOKINE; DNA; I KAPPA B; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYPHENOL; PROTEASOME; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UBIQUITIN; UNCLASSIFIED DRUG;

ANTIOXIDANT ACTIVITY; AORTA; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA BINDING; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

ANTHRANILIC ACIDS; AVENA SATIVA; CYTOKINES; ENDOTHELIUM, VASCULAR; GENES, REPORTER; HUMANS; INTERLEUKIN-1BETA; LUCIFERASES; NF-KAPPA B; PROTEASOME ENDOPEPTIDASE COMPLEX; TRANSFECTION;

AVENA;

EID: 38349015047     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.10.036     Document Type: Article

References (73)

1. Malloy M.J., and Kane J.P. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv. Intern. Med. 47 (2001) 111-136
2. Ross R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340 (1999) 115-126
3. Anderson J.W. Dietary fiber prevents carbohydrate-induced hypertriglyceridemia. Curr. Atheroscler. Rep. 2 (2000) 536-541
4. Ness A.R., and Powles J.W. Fruit and vegetables, and cardiovascular disease: a review. Int. J. Epidemiol. 26 (1997) 1-13
5. Gillman M.W., Cupples L.A., Gagnon D., Posner B.M., Ellison R.C., Castelli W.P., and Wolf P.A. Protective effect of fruits and vegetables on development of stroke in men. JAMA 273 (1995) 1113-1117
6. Joshipura K.J., Hu F.B., Manson J.E., Stampfer M.J., Rimm E.B., Speizer F.E., Colditz G., Ascherio A., Rosner B., Spiegelman D., and Willett W.C. The effect of fruit and vegetable intake on risk for coronary heart disease. Ann. Intern. Med. 134 (2001) 1106-1114
7. Jensen M.K., Koh-Banerjee P., Hu F.B., Franz M., Sampson L., Gronbaek M., and Rimm E.B. Intakes of whole grains, bran, and germ and the risk of coronary heart disease in men. Am. J. Clin. Nutr. 80 (2004) 1492-1499
8. Erkkila A.T., Herrington D.M., Mozaffarian D., and Lichtenstein A.H. Cereal fiber and whole-grain intake are associated with reduced progression of coronary-artery atherosclerosis in postmenopausal women with coronary artery disease. Am. Heart J. 150 (2005) 94-101
9. Mozaffarian D., Kumanyika S.K., Lemaitre R.N., Olson J.L., Burke G.L., and Siscovick D.S. Cereal, fruit, and vegetable fiber intake and the risk of cardiovascular disease in elderly individuals. JAMA 289 (2003) 1659-1666
10. Jacobs Jr. D.R., Meyer K.A., Kushi L.H., and Folsom A.R. Whole-grain intake may reduce the risk of ischemic heart disease death in postmenopausal women: the Iowa Women's Health Study. Am. J. Clin. Nutr. 68 (1998) 248-257
11. Jacobs Jr. D.R., Meyer K.A., Kushi L.H., and Folsom A.R. Is whole grain intake associated with reduced total and cause-specific death rates in older women? The Iowa Women's Health Study. Am. J. Public Health 89 (1999) 322-329
12. Liu S., Stampfer M.J., Hu F.B., Giovannucci E., Rimm E., Manson J.E., Hennekens C.H., and Willett W.C. Whole-grain consumption and risk of coronary heart disease: results from the Nurses' Health Study. Am. J. Clin. Nutr. 70 (1999) 412-419
13. Steffen L.M., Jacobs Jr. D.R., Stevens J., Shahar E., Carithers T., and Folsom A.R. Associations of whole-grain, refined-grain, and fruit and vegetable consumption with risks of all-cause mortality and incident coronary artery disease and ischemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Am. J. Clin. Nutr. 78 (2003) 383-390
14. Jacobs Jr. D.R., Meyer H.E., and Solvoll K. Reduced mortality among whole grain bread eaters in men and women in the Norwegian County Study. Eur. J. Clin. Nutr. 55 (2001) 137-143
15. Liu S., Sesso H.D., Manson J.E., Willett W.C., and Buring J.E. Is intake of breakfast cereals related to total and cause-specific mortality in men?. Am. J. Clin. Nutr. 77 (2003) 594-599
16. Slavin J., Jacobs D., and Marquart L. Whole-grain consumption and chronic disease: protective mechanisms. Nutr. Cancer 27 (1997) 14-21
17. Truswell A.S. Cereal grains and coronary heart disease. Eur. J. Clin. Nutr. 56 (2002) 1-14
18. Katz D.L., Nawaz H., Boukhalil J., Chan W., Ahmadi R., Giannamore V., and Sarrel P.M. Effects of oat and wheat cereals on endothelial responses. Prev. Med. 33 (2001) 476-484
19. Keenan J.M., Pins J.J., Frazel C., Moran A., and Turnquist L. Oat ingestion reduces systolic and diastolic blood pressure in patients with mild or borderline hypertension: a pilot trial. J. Fam. Pract. 51 (2002) 369
20. Saltzman E., Das S.K., Lichtenstein A.H., Dallal G.E., Corrales A., Schaefer E.J., Greenberg A.S., and Roberts S.B. An oat-containing hypocaloric diet reduces systolic blood pressure and improves lipid profile beyond effects of weight loss in men and women. J. Nutr. 131 (2001) 1465-1470
21. Nie L., Wise M.L., Peterson D.M., and Meydani M. Avenanthramide, a polyphenol from oats, inhibits vascular smooth muscle cell proliferation and enhances nitric oxide production. Atherosclerosis 186 (2006) 260-266
22. Collins F.W. Oat phenolics: avenanthramides, novel substituted N-cinnamoylanthranilate alkaloids from oat groats and hulls. J. Agric. Food Chem. 37 (1989) 60-66
23. Dimberg L.H., Theander O., and Lingnert H. Avenantrhramides: a group of phenolic antioxidants in oats. Cereal Chem. 70 (1993) 637-641
24. Peterson D.M. Oat antioxidants. J. Cereal Sci. 33 (2001) 115-229
25. Peterson D.M., Hahn M.J., and Emmons C.L. Oat avenanthramides exhibit antioxidant activities in vitro. Food Chem. 79 (2002) 473-478
26. Bratt K., Sunnerheim K., Bryngelsson S., Fagerlund A., Engman L., Andersson R.E., and Dimberg L.H. Avenanthramides in oats (Avena sativa L.) and structure-antioxidant activity relationships. J. Agric. Food Chem. 51 (2003) 594-600
27. Chen C.Y., Milbury P.E., Kwak H.K., Collins F.W., Samuel P., and Blumberg J.B. Avenanthramides and phenolic acids from oats are bioavailable and act synergistically with vitamin C to enhance hamster and human LDL resistance to oxidation. J. Nutr. 134 (2004) 1459-1466
28. Chen C., Milbury P., Li T., O'Leary J., and Blumberg J. Antioxidant capability and bioavailability of oat avenanthramides. FASEB J. 19 (2005) A1477
29. Chen C.Y., Milbury P.E., Collins F.W., and Blumberg J.B. Avenanthramides are bioavailable and have antioxidant activity in humans after acute consumption of an enriched mixture from oats. J. Nutr. 137 (2007) 1375-1382
30. Matsukawa T., Isobe T., Ishihara A., and Iwamura H. Occurrence of avenanthramides and hydroxycinnamoyl-CoA:hydroxyanthranilate N-hydroxycinnamoyltransferase activity in oat seeds. Z. Naturforsch. [C] 55 (2000) 30-36
31. Ji L.L., Lay D., Chung E., Fu Y., and Peterson D.M. Effects of avenanthramides on oxidant generation and antioxidant enzyme activity in exercised rats. Nutr. Res. 23 (2003) 1579-1590
32. Nie L., Wise M., Peterson D., and Meydani M. Mechanism by which avenanthramide-c, a polyphenol of oats, blocks cell cycle progression in vascular smooth muscle cells. Free Radic. Biol. Med. 41 (2006) 702-708
33. Liu L., Zubik L., Collins F.W., Marko M., and Meydani M. The antiatherogenic potential of oat phenolic compounds. Atherosclerosis 175 (2004) 39-49
34. Kulms D., and Schwarz T. NF-kappaB and cytokines. Vitam. Horm. 74 (2006) 283-300
35. Fieser L., and Fieser M. Reagents for organic synthesis (1967), Wiley-Interscience, New York
36. Rodriguez S.K., Guo W., Liu L., Band M.A., Paulson E.K., and Meydani M. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int. J. Cancer 118 (2005) 1635-1644
37. Renard P., Ernest I., Houbion A., Art M., Le Calvez H., Raes M., and Remacle J. Development of a sensitive multi-well colorimetric assay for active NFkappaB. Nucleic Acids Res. 29 (2001) E21
38. Manna S.K., Mukhopadhyay A., Van N.T., and Aggarwal B.B. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J. Immunol. 163 (1999) 6800-6809
39. He T.C., Zhou S., da Costa L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 2509-2514
40. Bocker U., Schottelius A., Watson J.M., Holt L., Licato L.L., Brenner D.A., Sartor R.B., and Jobin C. Cellular differentiation causes a selective down-regulation of interleukin (IL)-1beta-mediated NF-kappaB activation and IL-8 gene expression in intestinal epithelial cells. J. Biol. Chem. 275 (2000) 12207-12213
41. Rahman A., Anwar K.N., True A.L., and Malik A.B. Thrombin-induced p65 homodimer binding to downstream NF-kappa B site of the promoter mediates endothelial ICAM-1 expression and neutrophil adhesion. J. Immunol. 162 (1999) 5466-5476
42. Li W.G., Gavrila D., Liu X., Wang L., Gunnlaugsson S., Stoll L.L., McCormick M.L., Sigmund C.D., Tang C., and Weintraub N.L. Ghrelin inhibits proinflammatory responses and nuclear factor-kappaB activation in human endothelial cells. Circulation 109 (2004) 2221-2226
43. Darnay B.G., Ni J., Moore P.A., and Aggarwal B.B. Activation of NF-kappaB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-kappaB-inducing kinase. Identification of a novel TRAF6 interaction motif. J. Biol. Chem. 274 (1999) 7724-7731
44. Guo W., Shang F., Liu Q., Urim L., West-Mays J., and Taylor A. Differential regulation of components of the ubiquitin-proteasome pathway during lens cell differentiation. Invest. Ophthalmol. Vis. Sci. 45 (2004) 1194-1201
45. Rabilloud T., and Charmont S. Detection of proteins on two-dimensional electrophoresis gels (2000), Springer Verlag, Berlin/Heidelberg
46. Ledda-Columbano G.M., Pibiri M., Loi R., Perra A., Shinozuka H., and Columbano A. Early increase in cyclin-D1 expression and accelerated entry of mouse hepatocytes into S phase after administration of the mitogen 1, 4-bis[2-(3,5-dichloropyridyloxy)] benzene. Am. J. Pathol. 156 (2000) 91-97
47. Suzuki K., Kodama S., and Watanabe M. Recruitment of ATM protein to double strand DNA irradiated with ionizing radiation. J. Biol. Chem. 274 (1999) 25571-25575
48. Brunner M.C., Chambers C.A., Chan F.K., Hanke J., Winoto A., and Allison J.P. CTLA-4-mediated inhibition of early events of T cell proliferation. J. Immunol. 162 (1999) 5813-5820
49. Webb C.P., Hose C.D., Koochekpour S., Jeffers M., Oskarsson M., Sausville E., Monks A., and Vande Woude G.F. The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network. Cancer Res. 60 (2000) 342-349
50. Snyder J.G., Prewitt R., Campsen J., and Britt L.D. PDTC and Mg132, inhibitors of NF-kappaB, block endotoxin induced vasodilation of isolated rat skeletal muscle arterioles. Shock 17 (2002) 304-307
51. Delhase M., Hayakawa M., Chen Y., and Karin M. Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation. Science 284 (1999) 309-313
52. Saijo K., Mecklenbrauker I., Santana A., Leitger M., Schmedt C., and Tarakhovsky A. Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha. J. Exp. Med. 195 (2002) 1647-1652
53. Smith H.J., Wyke S.M., and Tisdale M.J. Mechanism of the attenuation of proteolysis-inducing factor stimulated protein degradation in muscle by beta-hydroxy-beta-methylbutyrate. Cancer Res. 64 (2004) 8731-8735
54. Wyke S.M., Russell S.T., and Tisdale M.J. Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation. Br. J. Cancer 91 (2004) 1742-1750
55. Lee D.H., and Goldberg A.L. Proteasome inhibitors: valuable new tools for cell biologists. Trends Cell Biol. 8 (1998) 397-403
56. Traenckner E.B., Wilk S., and Baeuerle P.A. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J. 13 (1994) 5433-5441
57. Palombella V.J., Rando O.J., Goldberg A.L., and Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 78 (1994) 773-785
58. Herrmann J., Ciechanover A., Lerman L.O., and Lerman A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc. Res. 61 (2004) 11-21
59. Herrmann J., Edwards W.D., Holmes Jr. D.R., Shogren K.L., Lerman L.O., Ciechanover A., and Lerman A. Increased ubiquitin immunoreactivity in unstable atherosclerotic plaques associated with acute coronary syndromes. J. Am. Coll. Cardiol. 40 (2002) 1919-1927
60. Raffaele M., D'Amico M., Esposito K., Baldi A., Di Filippo C., Siniscalchi M., Sasso F.C., Portoghese M., Cirillo F., Cacciapuoti F., Carbonara O., Crescenzi B., Baldi F., Ceriello A., Nicoletti G.F., D'Andrea F., Verza M., Coppola L., Rossi F., and Giugliano D. The ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatment. Diabetes 55 (2006) 622-632
61. Spiecker M., Lorenz I., Marx N., and Darius H. Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells. Mol. Pharmacol. 62 (2002) 856-863
62. Shishodia S., Amin H.M., Lai R., and Aggarwal B.B. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem. Pharmacol. 70 (2005) 700-713
63. Farid M., Reid M.B., Li Y.P., Gerken E., and Durham W.J. Effects of dietary curcumin or N-acetylcysteine on NF-kappaB activity and contractile performance in ambulatory and unloaded murine soleus. Nutr. Metab. (Lond.) 2 (2005) 20
64. Tsai S.H., Liang Y.C., Lin-Shiau S.Y., and Lin J.K. Suppression of TNFalpha-mediated NFkappaB activity by myricetin and other flavonoids through downregulating the activity of IKK in ECV304 cells. J. Cell. Biochem. 74 (1999) 606-615
65. Ishikawa Y., Sugiyama H., Stylianou E., and Kitamura M. Bioflavonoid quercetin inhibits interleukin-1-induced transcriptional expression of monocyte chemoattractant protein-1 in glomerular cells via suppression of nuclear factor-kappaB. J. Am. Soc. Nephrol. 10 (1999) 2290-2296
66. Peet G.W., and Li J. IkappaB kinases alpha and beta show a random sequential kinetic mechanism and are inhibited by staurosporine and quercetin. J. Biol. Chem. 274 (1999) 32655-32661
67. Comalada M., Camuesco D., Sierra S., Ballester I., Xaus J., Galvez J., and Zarzuelo A. In vivo quercitrin anti-inflammatory effect involves release of quercetin, which inhibits inflammation through down-regulation of the NF-kappaB pathway. Eur. J. Immunol. 35 (2005) 584-592
68. Pellegatta F., Bertelli A.A., Staels B., Duhem C., Fulgenzi A., and Ferrero M.E. Different short- and long-term effects of resveratrol on nuclear factor-kappaB phosphorylation and nuclear appearance in human endothelial cells. Am. J. Clin. Nutr. 77 (2003) 1220-1228
69. Kundu J.K., and Surh Y.J. Molecular basis of chemoprevention by resveratrol: NF-kappaB and AP-1 as potential targets. Mutat. Res. 555 (2004) 65-80
70. Tsai S.H., Lin-Shiau S.Y., and Lin J.K. Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br. J. Pharmacol. 126 (1999) 673-680
71. Aktas O., Prozorovski T., Smorodchenko A., Savaskan N.E., Lauster R., Kloetzel P.M., Infante-Duarte C., Brocke S., and Zipp F. Green tea epigallocatechin-3-gallate mediates T cellular NF-kappa B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173 (2004) 5794-5800
72. Ahn S.C., Kim G.Y., Kim J.H., Baik S.W., Han M.K., Lee H.J., Moon D.O., Lee C.M., Kang J.H., Kim B.H., Oh Y.H., and Park Y.M. Epigallocatechin-3-gallate, constituent of green tea, suppresses the LPS-induced phenotypic and functional maturation of murine dendritic cells through inhibition of mitogen-activated protein kinases and NF-kappaB. Biochem. Biophys. Res. Commun. 313 (2004) 148-155
73. Lin Y.L., and Lin J.K. (-)-Epigallocatechin-3-gallate blocks the induction of nitric oxide synthase by down-regulating lipopolysaccharide-induced activity of transcription factor nuclear factor-kappaB. Mol. Pharmacol. 52 (1997) 465-472